

Ocrevus (Ocrelizumab) Infusion Orders

Patient Name: _____ DOB: _____ Male Female

Diagnosis (please provide ICD10 code) _____

Other: _____

NKDA Allergies: _____

New Start Therapy Continuation of Therapy Date of last dose (if applicable): _____

Ordering Provider: _____

Provider NPI: _____ Phone: _____ Fax: _____

Practice Address: _____ City: _____ State: _____ Zip Code: _____

PRE-MEDICATIONS

- Acetaminophen 1000mg PO, Diphenhydramine 50mg IV, and Solu-Medrol 125mg IV

**Patient will receive above premeds per Sage Infusion Medication Safety Protocol unless different premeds are noted below*

Other PreMeds: _____

REQUIRED LABS

- Clinical/Progress Notes, Labs, Tests supporting primary diagnosis (please attach)
- Hepatitis B status & date (please attach results): _____

OCREVUS ORDERS

INDUCTION DOSE:

- Induction Dose: 300mg in 250ml 0.9% sodium chloride intravenous infusion at Day 1 and Day 15

Rate: Start at 30ml/hr, increasing by 30ml/hr every 30 minutes to a maximum rate of 180ml/hr (to be given in no less than 2.5 hours)

- After Induction Dose, continue with Maintenance Dose below

MAINTENANCE DOSE:

- 600mg in 500ml 0.9% sodium chloride intravenous infusion every 6 months

Infuse over 3.5 hours: Start at 40ml/hr, increase by 40ml/hr every 30 minutes, max 200ml/hr

If patient has not experienced any prior serious infusion reactions, infusion can be given over 2 hours: Start at 100ml/hr x15 min, 200ml/hr x15 min, 250ml/hr x30 min, 300ml/hr remainder of infusion

REFILLS:

(if not indicated order will expire one year from date signed)

- Sage Infusion Standing Orders:**

Provide treatment under Sage Infusion's Clinical Guidelines, Medication Safety Protocol, Emergency Guidelines, and Action Plan for Infusion Reactions.

Provider Name

Provider Signature

Date

Hepatitis B virus and quantitative serum immunoglobulin screening are required before the first dose.

Infections: Delay Ocrevus administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with Ocrevus and after discontinuation, until B-cell repletion.

Monitor patients closely during and for at least one hour after infusion